» Articles » PMID: 15010838

Conventional and Array-based Comparative Genomic Hybridization Analyses of Novel Cell Lines Harboring HPV18 from Glassy Cell Carcinoma of the Uterine Cervix

Overview
Journal Int J Oncol
Specialty Oncology
Date 2004 Mar 11
PMID 15010838
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

We established 2 novel human cell lines (GCCOT-1, GCCRK) from glassy cell carcinoma. Both cell lines showed dual tendencies of glandular and squamous differentiation, and thus possess the characteristics resembling reserve cells, the putative origin of most carcinomas arising from the uterine cervix. HPV type 18 DNA including E6-E7, which is commonly found in cell types other than squamous cell carcinoma of uterine cervix, was detected in both cell lines. We analyzed gene copy number alterations of the 2 cell lines using conventional comparative genomic hybridization (CGH) coupled with array-based CGH. Among the putative oncogenes demonstrating copy number gain in both cell lines, FGR(SRC2) at 1p36.2-1 and LAMC2 at 1q25-31 have not been reported to show amplification in previous analyses of conventional cervical cell lines. These oncogenes are thus speculated to be directly associated with oncogenesis of glassy cell carcinoma. On the other hand, among the putative suppressor genes demonstrating copy number loss in both cell lines, the 9q region, ATM at 11q22.3, and CYLD at 16q12-13 have not been reported to show loss in conventional cervical cancer cell lines. These sites are speculated to be important as tumor suppressors directly associated with oncogenesis of glassy cell carcinoma. This study suggests for the first time that together with the presence of HPV type 18, alterations at the above sites are closely associated with oncogenesis of glassy cell carcinoma, a special type of carcinoma in the uterine cervix.

Citing Articles

CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers.

Cui Z, Kang H, Grandis J, Johnson D Mol Cancer Res. 2020; 19(1):14-24.

PMID: 32883697 PMC: 7840145. DOI: 10.1158/1541-7786.MCR-20-0565.


Copy number variation of ubiquitin- specific proteases genes in blood leukocytes and colorectal cancer.

Tian T, Bi H, Liu Y, Li G, Zhang Y, Cao L Cancer Biol Ther. 2020; 21(7):637-646.

PMID: 32364424 PMC: 7515516. DOI: 10.1080/15384047.2020.1750860.


Role of Deubiquitinases in Human Cancers: Potential Targeted Therapy.

Lai K, Chen J, Tse W Int J Mol Sci. 2020; 21(7).

PMID: 32268558 PMC: 7177317. DOI: 10.3390/ijms21072548.


Deubiquitinating Enzymes: A Critical Regulator of Mitosis.

Park J, Cho J, Kim E, Song E Int J Mol Sci. 2019; 20(23).

PMID: 31795161 PMC: 6929034. DOI: 10.3390/ijms20235997.


Cylindromatosis Tumor Suppressor Protein (CYLD) Deubiquitinase is Necessary for Proper Ubiquitination and Degradation of the Epidermal Growth Factor Receptor.

Sanchez-Quiles V, Akimov V, Osinalde N, Francavilla C, Puglia M, Barrio-Hernandez I Mol Cell Proteomics. 2017; 16(8):1433-1446.

PMID: 28572092 PMC: 5546196. DOI: 10.1074/mcp.M116.066423.